CD19 CAR mRNA (m1Ψ, Cap1)
 
The CD19 CAR mRNA encodes a chimeric antigen receptor (CAR) engineered to specifically recognize the CD19 antigen expressed on B cells. This mRNA enables transient CAR expression in immune effector cells such as T cells or NK cells, facilitating the targeted elimination of CD19⁺ cells. The CAR construct typically integrates an extracellular scFv specific to CD19, a hinge and transmembrane region, and intracellular signaling domains (e.g., CD28 or 4‑1BB and CD3ζ) that drive robust activation and cellular persistence.
 
Designed for efficient and reliable in vitro transfection, PreciGenome’s CD19 CAR mRNA provides a high-quality, non-integrating reagent for CAR-T and CAR-NK cell generation. It is an ideal research-grade tool for studying B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma models.
 
Product Features
High-efficiency Cap1 structure for enhanced mRNA translation.
100% substitution with N1‑methyl‑pseudouridine (m1Ψ) for improved protein expression and reduced innate immune activation.
100A poly(A) tail mimics natural mRNA for stable expression.
Transient and non-integrating expression—ideal for preclinical or mechanistic studies.
 
Product Specifications
Form: Liquid
Concentration: 1 mg/mL
Full mRNA Length: 1789 nt
Molecular Weight: 578,298 Da
Buffer: 1 mM Sodium citrate, pH 6.5
Storage: Store at –20 °C (short term, <3 months) or –80 °C (long term).
Shipping Method: Dry ice
 
Quality Control
Appearance: Clear, free of foreign particles
RNA Length: Expected size band detected
RNA Content: Target ± 5%
Integrity: ≥ 75%
OD260/OD280: 1.70–2.30
Capping Efficiency: ≥ 90%
Endotoxin: < 10 EU/mg
pH: Target ± 0.5
For research use only.

Contact us for custom formulations or special requests.